DuoGenic StemCells (ROCO:7607) Operating Margin %: -117.96% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7607 DuoGenic StemCells Corp ROCO:7607
25 GF Score
Price NT$13.00
GF Value NT$51.22
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is DuoGenic StemCells Operating Margin %?

DuoGenic StemCells ROCO:7607 -0.76% 25 Operating Margin % is -117.96% as of Dec. 2025. GuruFocus rates ROCO:7607 with a GF Score™ of 25/100 and a GF Value™ of NT$51.22 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 940 Biotechnology companies, DuoGenic StemCells ranks worse than 54.04% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. DuoGenic StemCells's Operating Income for the six months ended in Dec. 2025 was NT$-12.14 Mil. DuoGenic StemCells's Revenue for the six months ended in Dec. 2025 was NT$10.29 Mil. Therefore, DuoGenic StemCells's Operating Margin % for the quarter that ended in Dec. 2025 was -117.96%.

The historical rank and industry rank for DuoGenic StemCells's Operating Margin % or its related term are showing as below:

ROCO:7607' s Operating Margin % Range Over the Past 10 Years
Min: -1007.49   Med: -488.53   Max: -124.65
Current: -124.65


ROCO:7607's Operating Margin % is ranked worse than
54.04% of 940 companies
in the Biotechnology industry
Industry Median: -86.55 vs ROCO:7607: -124.65

DuoGenic StemCells's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

DuoGenic StemCells's Operating Income for the six months ended in Dec. 2025 was NT$-12.14 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-25.79 Mil.

Warning Sign:

DuoGenic StemCells Corp has never been profitable in the past 3 years. It lost money every year.


DuoGenic StemCells  (ROCO:7607) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


DuoGenic StemCells Operating Margin % Related Terms


DuoGenic StemCells Operating Margin % Historical Data

* Premium members only.

The historical data trend for DuoGenic StemCells's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DuoGenic StemCells Operating Margin % Chart

DuoGenic StemCells Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
-1,007.49 -488.53 -328.42 -506.23 -124.65

DuoGenic StemCells Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only -362.20 -643.07 -406.12 -131.26 -117.96

ROCO:7607 vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, DuoGenic StemCells's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DuoGenic StemCells Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's Operating Margin % distribution charts can be found below:

* The bar in red indicates where DuoGenic StemCells's Operating Margin % falls into.


ROCO:7607
25GF Score
DuoGenic StemCells Corp ROCO:7607
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DuoGenic StemCells Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

DuoGenic StemCells's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-25.793 / 20.693
=-124.65 %

DuoGenic StemCells's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-12.137 / 10.289
=-117.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -117.96% mean?
DuoGenic StemCells (ROCO:7607) has a Operating Margin % of -117.96% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on DuoGenic StemCells and its competitors. According to the industry distribution chart, DuoGenic StemCells ranks #508 out of 940 companies in the Biotechnology industry, placing it in the top 54%.
Is DuoGenic StemCells' Operating Margin % too high?
DuoGenic StemCells' current Operating Margin % is -117.96%. Based on the distribution chart, DuoGenic StemCells ranks #508 out of 940 companies in the Biotechnology industry, which is below the industry midpoint. Overall, DuoGenic StemCells has a GF Score™ of 25/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DuoGenic StemCells' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DuoGenic StemCells ranks #508 out of 940 companies for Operating Margin %. This places DuoGenic StemCells in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on DuoGenic StemCells and its competitors. DuoGenic StemCells's current Operating Margin % is -117.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DuoGenic StemCells stock overvalued right now?
Based on GuruFocus' analysis, DuoGenic StemCells (ROCO:7607) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$51.22, compared to a current price of NT$13.00 — trading 74.6% below its estimated fair value. The current Operating Margin % is -117.96%. DuoGenic StemCells' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For DuoGenic StemCells (ROCO:7607), the current Operating Margin % is -117.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DuoGenic StemCells (ROCO:7607) Overvalued in 2026?

Based on GuruFocus' analysis, DuoGenic StemCells stock appears to be undervalued. The current stock price of NT$13.00 is trading 74.6% below its estimated GF Value™ of NT$51.22. GuruFocus considers DuoGenic StemCells to be Significantly Undervalued.

Key valuation signals for ROCO:7607:

  • Operating Margin %: -117.96%
  • GF Value™: NT$51.22 vs. price of NT$13.00 (74.6% below fair value)
  • GF Score™: 25/100 with 2 warning signs

No single metric tells the full story. See the ROCO:7607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


DuoGenic StemCells Business Description

Address Room R207, Innovation Incubation Center, 145, Xingda Road, South District, Taichung, TWN
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.
25GF Score

Get the complete analysis for ROCO:7607

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$13.00
Price
NT$51.22
GF Value